| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 32 | 2024 | 1180 | 4.410 |
Why?
|
| Antiviral Agents | 13 | 2024 | 478 | 2.190 |
Why?
|
| Hepatitis C | 8 | 2024 | 172 | 2.130 |
Why?
|
| Liver Cirrhosis | 12 | 2017 | 256 | 2.080 |
Why?
|
| Tissue Donors | 9 | 2024 | 494 | 1.970 |
Why?
|
| Hepacivirus | 8 | 2024 | 130 | 1.860 |
Why?
|
| Organ Transplantation | 5 | 2024 | 276 | 1.710 |
Why?
|
| Hepatitis C, Chronic | 7 | 2019 | 91 | 1.470 |
Why?
|
| Hepatitis B | 2 | 2024 | 76 | 1.240 |
Why?
|
| Immunosuppressive Agents | 12 | 2022 | 975 | 1.190 |
Why?
|
| Tissue and Organ Procurement | 4 | 2024 | 347 | 1.160 |
Why?
|
| Hepatitis B virus | 3 | 2024 | 44 | 1.060 |
Why?
|
| Hepatitis B Antibodies | 1 | 2024 | 16 | 0.950 |
Why?
|
| Virus Activation | 1 | 2024 | 42 | 0.930 |
Why?
|
| Liver Failure | 3 | 2019 | 67 | 0.850 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2016 | 19 | 0.770 |
Why?
|
| End Stage Liver Disease | 4 | 2024 | 60 | 0.720 |
Why?
|
| Viral Load | 3 | 2019 | 145 | 0.710 |
Why?
|
| Liver Diseases | 5 | 2021 | 242 | 0.680 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2014 | 66 | 0.640 |
Why?
|
| Intestinal Polyps | 1 | 2018 | 27 | 0.630 |
Why?
|
| Stomach Diseases | 1 | 2018 | 19 | 0.630 |
Why?
|
| Duodenal Diseases | 1 | 2018 | 23 | 0.630 |
Why?
|
| Hypertension, Portal | 1 | 2018 | 46 | 0.620 |
Why?
|
| Gastric Mucosa | 1 | 2018 | 67 | 0.610 |
Why?
|
| Ribavirin | 5 | 2016 | 40 | 0.610 |
Why?
|
| Liver Neoplasms | 7 | 2021 | 758 | 0.590 |
Why?
|
| Graft Survival | 7 | 2023 | 900 | 0.580 |
Why?
|
| Rifamycins | 1 | 2016 | 6 | 0.560 |
Why?
|
| Hepatorenal Syndrome | 1 | 2016 | 9 | 0.560 |
Why?
|
| Middle Aged | 37 | 2024 | 25974 | 0.550 |
Why?
|
| Heart Transplantation | 4 | 2021 | 717 | 0.550 |
Why?
|
| Humans | 70 | 2024 | 89357 | 0.540 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 91 | 0.520 |
Why?
|
| Male | 46 | 2024 | 42411 | 0.520 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1047 | 0.510 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 12 | 0.500 |
Why?
|
| Graft Rejection | 7 | 2022 | 1070 | 0.490 |
Why?
|
| Zinc | 1 | 2015 | 93 | 0.480 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2014 | 19 | 0.480 |
Why?
|
| Liver Failure, Acute | 1 | 2014 | 39 | 0.470 |
Why?
|
| Female | 43 | 2024 | 46202 | 0.460 |
Why?
|
| Hepatitis E | 1 | 2013 | 5 | 0.440 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2021 | 394 | 0.420 |
Why?
|
| Kidney Transplantation | 3 | 2022 | 850 | 0.420 |
Why?
|
| Interferon-alpha | 3 | 2011 | 226 | 0.420 |
Why?
|
| Pharmacy | 2 | 2022 | 9 | 0.420 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 17 | 0.410 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 312 | 0.410 |
Why?
|
| Postoperative Complications | 6 | 2019 | 2284 | 0.410 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 142 | 0.400 |
Why?
|
| RNA, Viral | 5 | 2024 | 317 | 0.400 |
Why?
|
| Donor Selection | 1 | 2012 | 74 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 601 | 0.390 |
Why?
|
| Hospitals | 2 | 2021 | 299 | 0.380 |
Why?
|
| Hepatic Encephalopathy | 2 | 2023 | 39 | 0.380 |
Why?
|
| Biopsy | 5 | 2018 | 1184 | 0.350 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2018 | 43 | 0.340 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 445 | 0.330 |
Why?
|
| DNA, Viral | 2 | 2024 | 262 | 0.320 |
Why?
|
| Lung Transplantation | 2 | 2022 | 292 | 0.310 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 793 | 0.300 |
Why?
|
| United States | 11 | 2023 | 6989 | 0.300 |
Why?
|
| Marfan Syndrome | 1 | 2007 | 28 | 0.300 |
Why?
|
| Endoscopy, Digestive System | 1 | 2007 | 68 | 0.290 |
Why?
|
| Polyethylene Glycols | 2 | 2010 | 358 | 0.290 |
Why?
|
| Aged | 20 | 2022 | 19165 | 0.290 |
Why?
|
| Hernia, Hiatal | 1 | 2007 | 38 | 0.280 |
Why?
|
| Gastroenterology | 2 | 2021 | 144 | 0.280 |
Why?
|
| Advisory Committees | 2 | 2024 | 89 | 0.280 |
Why?
|
| Adult | 24 | 2021 | 26607 | 0.270 |
Why?
|
| Living Donors | 2 | 2023 | 339 | 0.270 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2003 | 29 | 0.260 |
Why?
|
| Hepatitis B, Chronic | 2 | 2016 | 32 | 0.260 |
Why?
|
| Liver | 4 | 2017 | 1208 | 0.260 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 3666 | 0.260 |
Why?
|
| Guanine | 2 | 2016 | 207 | 0.250 |
Why?
|
| Treatment Outcome | 15 | 2022 | 8241 | 0.250 |
Why?
|
| Mycophenolic Acid | 1 | 2005 | 84 | 0.240 |
Why?
|
| Cimicifuga | 1 | 2004 | 3 | 0.240 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2024 | 10 | 0.240 |
Why?
|
| Hepatitis | 3 | 2001 | 34 | 0.240 |
Why?
|
| Cyclosporine | 2 | 2003 | 237 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2566 | 0.230 |
Why?
|
| Cholestasis | 1 | 2004 | 45 | 0.230 |
Why?
|
| Retrospective Studies | 14 | 2017 | 9057 | 0.220 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.220 |
Why?
|
| Hypophosphatemia | 1 | 2003 | 7 | 0.220 |
Why?
|
| Phytotherapy | 1 | 2004 | 136 | 0.220 |
Why?
|
| Phosphorus | 1 | 2003 | 117 | 0.210 |
Why?
|
| Nucleic Acids | 1 | 2023 | 32 | 0.210 |
Why?
|
| Streptococcus | 1 | 2002 | 8 | 0.210 |
Why?
|
| Plant Extracts | 1 | 2004 | 245 | 0.210 |
Why?
|
| Transgender Persons | 1 | 2024 | 107 | 0.200 |
Why?
|
| Streptococcal Infections | 1 | 2002 | 56 | 0.200 |
Why?
|
| Risk Factors | 8 | 2022 | 5499 | 0.200 |
Why?
|
| Genotype | 4 | 2013 | 1849 | 0.200 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2004 | 203 | 0.190 |
Why?
|
| Incidence | 5 | 2022 | 1595 | 0.190 |
Why?
|
| Bacteremia | 1 | 2002 | 102 | 0.190 |
Why?
|
| Transplant Recipients | 2 | 2021 | 137 | 0.190 |
Why?
|
| Fistula | 1 | 2021 | 42 | 0.190 |
Why?
|
| Folic Acid Antagonists | 1 | 2000 | 19 | 0.190 |
Why?
|
| Foreign-Body Migration | 1 | 2001 | 39 | 0.180 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2020 | 16 | 0.180 |
Why?
|
| Gilbert Disease | 1 | 2000 | 1 | 0.180 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Gastroenterologists | 1 | 2021 | 31 | 0.180 |
Why?
|
| Job Satisfaction | 1 | 2021 | 78 | 0.180 |
Why?
|
| Methotrexate | 1 | 2000 | 250 | 0.170 |
Why?
|
| Allografts | 2 | 2019 | 181 | 0.170 |
Why?
|
| Internal Medicine | 2 | 2021 | 355 | 0.170 |
Why?
|
| Heart Failure | 3 | 2019 | 1185 | 0.170 |
Why?
|
| Drug Therapy, Combination | 6 | 2016 | 784 | 0.170 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 1999 | 14 | 0.170 |
Why?
|
| Alanine Transaminase | 2 | 2013 | 72 | 0.170 |
Why?
|
| Internship and Residency | 2 | 2021 | 1045 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2002 | 260 | 0.170 |
Why?
|
| Liver Function Tests | 2 | 2013 | 92 | 0.170 |
Why?
|
| Isoenzymes | 1 | 2000 | 274 | 0.170 |
Why?
|
| Autoimmune Diseases | 2 | 2001 | 249 | 0.170 |
Why?
|
| Multiple Organ Failure | 1 | 2019 | 53 | 0.160 |
Why?
|
| Burnout, Professional | 1 | 2021 | 102 | 0.160 |
Why?
|
| Curriculum | 2 | 2021 | 568 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2000 | 186 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 1840 | 0.150 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 262 | 0.150 |
Why?
|
| Time Factors | 5 | 2017 | 5338 | 0.150 |
Why?
|
| Stents | 1 | 2001 | 405 | 0.150 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 363 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 353 | 0.150 |
Why?
|
| Q Fever | 1 | 2017 | 8 | 0.150 |
Why?
|
| Patient Selection | 2 | 2020 | 684 | 0.150 |
Why?
|
| Sustained Virologic Response | 1 | 2017 | 5 | 0.150 |
Why?
|
| Opiate Substitution Treatment | 1 | 2017 | 40 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2018 | 157 | 0.140 |
Why?
|
| Uridine Monophosphate | 1 | 2016 | 4 | 0.140 |
Why?
|
| Fluorenes | 1 | 2016 | 6 | 0.140 |
Why?
|
| Fatal Outcome | 2 | 2014 | 299 | 0.140 |
Why?
|
| Midodrine | 1 | 2016 | 4 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2016 | 683 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 851 | 0.140 |
Why?
|
| Paracentesis | 1 | 2016 | 10 | 0.140 |
Why?
|
| Recurrence | 4 | 2016 | 1144 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 56 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2017 | 175 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2001 | 475 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 56 | 0.130 |
Why?
|
| Students, Medical | 1 | 2021 | 419 | 0.130 |
Why?
|
| Health Policy | 1 | 2017 | 185 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2016 | 111 | 0.130 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 59 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2017 | 2303 | 0.130 |
Why?
|
| Young Adult | 6 | 2021 | 6312 | 0.130 |
Why?
|
| Survival Rate | 2 | 2021 | 1901 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 860 | 0.130 |
Why?
|
| Hospitalization | 3 | 2016 | 877 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2019 | 575 | 0.120 |
Why?
|
| Macrocyclic Compounds | 1 | 2014 | 8 | 0.120 |
Why?
|
| Comorbidity | 2 | 2017 | 949 | 0.120 |
Why?
|
| Carbamates | 1 | 2014 | 15 | 0.120 |
Why?
|
| HIV Infections | 1 | 2004 | 840 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 151 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 988 | 0.120 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 141 | 0.120 |
Why?
|
| Anilides | 1 | 2014 | 48 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2015 | 125 | 0.120 |
Why?
|
| Melanoma | 1 | 1999 | 468 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 306 | 0.120 |
Why?
|
| Esophagitis | 1 | 2014 | 43 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 191 | 0.120 |
Why?
|
| Prognosis | 3 | 2021 | 3783 | 0.120 |
Why?
|
| Autoantibodies | 2 | 2014 | 268 | 0.120 |
Why?
|
| Career Choice | 3 | 2021 | 148 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 97 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2000 | 762 | 0.110 |
Why?
|
| ABO Blood-Group System | 1 | 2014 | 58 | 0.110 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2016 | 2872 | 0.110 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 463 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2000 | 739 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 580 | 0.110 |
Why?
|
| Hepatitis E virus | 1 | 2013 | 5 | 0.110 |
Why?
|
| Roseolovirus Infections | 1 | 2013 | 7 | 0.110 |
Why?
|
| Disease Progression | 2 | 2015 | 1489 | 0.110 |
Why?
|
| Sirolimus | 1 | 2014 | 170 | 0.110 |
Why?
|
| Herpesvirus 6, Human | 1 | 2013 | 19 | 0.110 |
Why?
|
| Ganciclovir | 1 | 2013 | 49 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 444 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2014 | 162 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 75 | 0.110 |
Why?
|
| Isoantibodies | 1 | 2014 | 119 | 0.110 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 469 | 0.110 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2012 | 21 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 179 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2014 | 227 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6811 | 0.100 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 996 | 0.100 |
Why?
|
| Hospitalists | 1 | 2014 | 135 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 91 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1862 | 0.100 |
Why?
|
| Fatty Liver | 1 | 2012 | 95 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 178 | 0.100 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 1012 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 971 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2014 | 385 | 0.090 |
Why?
|
| Consensus | 2 | 2022 | 356 | 0.090 |
Why?
|
| Mass Screening | 1 | 2015 | 636 | 0.090 |
Why?
|
| Molecular Epidemiology | 1 | 2010 | 53 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 509 | 0.080 |
Why?
|
| Biliary Fistula | 1 | 2009 | 11 | 0.080 |
Why?
|
| Respiratory Tract Fistula | 1 | 2009 | 9 | 0.080 |
Why?
|
| Toxocariasis | 1 | 2008 | 2 | 0.080 |
Why?
|
| Neoplasms | 1 | 2004 | 3041 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2016 | 950 | 0.080 |
Why?
|
| Global Health | 1 | 2010 | 187 | 0.080 |
Why?
|
| Adolescent | 5 | 2019 | 9263 | 0.080 |
Why?
|
| Gastroscopy | 1 | 2007 | 25 | 0.070 |
Why?
|
| Waiting Lists | 2 | 2019 | 184 | 0.070 |
Why?
|
| Aortic Rupture | 1 | 2007 | 57 | 0.070 |
Why?
|
| Esophagoscopy | 1 | 2007 | 90 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2001 | 345 | 0.070 |
Why?
|
| Hepatitis B e Antigens | 2 | 2016 | 7 | 0.070 |
Why?
|
| Biomarkers | 1 | 2013 | 1767 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 711 | 0.070 |
Why?
|
| Calcineurin Inhibitors | 2 | 2016 | 53 | 0.060 |
Why?
|
| Amantadine | 1 | 2005 | 18 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 788 | 0.060 |
Why?
|
| Retreatment | 1 | 2005 | 108 | 0.060 |
Why?
|
| Prevalence | 2 | 2021 | 1243 | 0.060 |
Why?
|
| Hot Flashes | 1 | 2004 | 12 | 0.060 |
Why?
|
| Prednisone | 2 | 2003 | 259 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2005 | 192 | 0.060 |
Why?
|
| Gender Dysphoria | 1 | 2024 | 9 | 0.060 |
Why?
|
| Hospital Costs | 2 | 2016 | 109 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 233 | 0.060 |
Why?
|
| Complementary Therapies | 1 | 2004 | 56 | 0.060 |
Why?
|
| Logistic Models | 3 | 2012 | 1213 | 0.060 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2005 | 101 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2024 | 85 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2021 | 784 | 0.060 |
Why?
|
| Bile Ducts | 1 | 2003 | 59 | 0.050 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2005 | 114 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 895 | 0.050 |
Why?
|
| Blood Donors | 1 | 2023 | 22 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 266 | 0.050 |
Why?
|
| Chickenpox Vaccine | 1 | 2002 | 7 | 0.050 |
Why?
|
| Arthroplasty, Replacement | 1 | 2003 | 37 | 0.050 |
Why?
|
| Glucocorticoids | 2 | 2003 | 358 | 0.050 |
Why?
|
| Chickenpox | 1 | 2002 | 39 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2005 | 871 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 922 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2003 | 369 | 0.050 |
Why?
|
| Animals | 3 | 2023 | 27371 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2003 | 293 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 309 | 0.050 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 58 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2624 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2021 | 22 | 0.050 |
Why?
|
| Training Support | 1 | 2021 | 23 | 0.050 |
Why?
|
| Bilirubin | 1 | 2021 | 131 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2000 | 21 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1799 | 0.040 |
Why?
|
| Medicine | 1 | 2021 | 91 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2021 | 170 | 0.040 |
Why?
|
| Cholangitis | 1 | 1999 | 19 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 231 | 0.040 |
Why?
|
| Transition to Adult Care | 1 | 2019 | 22 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 322 | 0.040 |
Why?
|
| Physician's Role | 1 | 2021 | 177 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2019 | 3731 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 1999 | 148 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 425 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 385 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 1723 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2019 | 231 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 657 | 0.040 |
Why?
|
| Doxycycline | 1 | 2017 | 28 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 1997 | 64 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 784 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2017 | 130 | 0.040 |
Why?
|
| Adiposity | 1 | 2017 | 76 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 2661 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 96 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2016 | 7 | 0.040 |
Why?
|
| Necrosis | 1 | 1997 | 209 | 0.040 |
Why?
|
| Sofosbuvir | 1 | 2016 | 9 | 0.040 |
Why?
|
| Azathioprine | 1 | 1997 | 124 | 0.040 |
Why?
|
| Alleles | 1 | 2000 | 1135 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 111 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1263 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 203 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 69 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2015 | 23 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 227 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 428 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 451 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 371 | 0.030 |
Why?
|
| Pediatrics | 1 | 2019 | 353 | 0.030 |
Why?
|
| 2-Naphthylamine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Lactams, Macrocyclic | 1 | 2014 | 14 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2014 | 25 | 0.030 |
Why?
|
| Ritonavir | 1 | 2014 | 12 | 0.030 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 196 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 146 | 0.030 |
Why?
|
| Uracil | 1 | 2014 | 55 | 0.030 |
Why?
|
| Proline | 1 | 2014 | 55 | 0.030 |
Why?
|
| Valine | 1 | 2014 | 62 | 0.030 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 40 | 0.030 |
Why?
|
| Child | 2 | 2019 | 7174 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 610 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2014 | 25 | 0.030 |
Why?
|
| Transaminases | 1 | 2014 | 33 | 0.030 |
Why?
|
| Complement C4b | 1 | 2014 | 32 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 773 | 0.030 |
Why?
|
| Spouses | 1 | 2014 | 32 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 137 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 65 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 387 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 461 | 0.030 |
Why?
|
| Heart Block | 1 | 2012 | 31 | 0.030 |
Why?
|
| Fractures, Bone | 2 | 2005 | 128 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 736 | 0.030 |
Why?
|
| Infant | 1 | 2019 | 3160 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 4289 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2014 | 318 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 856 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 230 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2014 | 463 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2015 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2012 | 107 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 199 | 0.020 |
Why?
|
| Inpatients | 1 | 2014 | 310 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2014 | 395 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2010 | 82 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 287 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 233 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2758 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 11761 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 374 | 0.020 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2009 | 12 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2012 | 279 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 739 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2009 | 66 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2009 | 64 | 0.020 |
Why?
|
| Mutation | 1 | 2000 | 4143 | 0.020 |
Why?
|
| Cats | 1 | 2008 | 305 | 0.020 |
Why?
|
| Cadaver | 1 | 2007 | 185 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1224 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2007 | 78 | 0.020 |
Why?
|
| Hypertension | 1 | 2012 | 745 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2007 | 170 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1150 | 0.020 |
Why?
|
| Emergencies | 1 | 2005 | 121 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2007 | 1534 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 2005 | 126 | 0.010 |
Why?
|
| Stroke | 1 | 2012 | 986 | 0.010 |
Why?
|
| Osteonecrosis | 1 | 2003 | 22 | 0.010 |
Why?
|
| Arthritis | 1 | 2003 | 47 | 0.010 |
Why?
|
| Acyclovir | 1 | 2002 | 108 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2003 | 302 | 0.010 |
Why?
|
| Hepatitis Antibodies | 1 | 2001 | 6 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2003 | 266 | 0.010 |
Why?
|
| Interferons | 1 | 2001 | 126 | 0.010 |
Why?
|
| Syndrome | 1 | 2001 | 449 | 0.010 |
Why?
|